The NULISAqpcr AD 5-plex Assay integrates biomarkers across the ATNI framework – Amyloid (A), Tau (T), and Neurodegeneration (N) and Inflammation (I) to enable earlier detection, resolution of disease heterogeneity, and better prediction of therapeutic outcomes in Alzheimer’s Disease research.
The AD 5-plex assay provides the possibility of an integrated understanding of Alzheimer’s pathology with simultaneous quantitative measurement of five key biomarkers – BD-pTau217, NfL, Aβ42, GFAP, and APOE4 carrier status – from a single, non-invasive blood or plasma sample.
Precision Proteomics
Only multiplexed panel to combine the sensitivity and specificity necessary to integrate protein markers and carrier status assessment for a complete picture of Alzheimer’s pathology.
Integrated analysis from minimal sample input
Simultaneous measurement of BD-pTau217, Aβ42, NfL, and GFAP and APOE4 from a single 35µL sample.
Non-Invasive Sample
Obtain robust results from standard blood draws, streamlining collection and processing.
Automated Workflow
Efficiently analyse up to 252 samples in just 8 hours with less than 30-min of hands-on time for laboratory staff.
Alamar Biosciences is dedicated to redefining risk and progression monitoring in neurodegenerative diseases. By moving beyond single-analyte testing, NULISAqpcr AD 5-Plex Assay provides a multidimensional profile to support a more accurate interpretation of Alzheimer’s disesase biology.
BD-pTau217 is a highly specific indicator of amyloid and tau protein abnormalities in the brain. Its elevated levels reflect the presence of amyloid plaque and tau tangles, which are the defining features of Alzheimer’s disease pathology. By detecting BD-pTau217 in blood, clinicians and researchers can monitor the progression of neurofibrillary degeneration non-invasively, making it a powerful tool for early detection and tracking disease dynamics over time.
A core neuropathological hallmark of Alzheimer’s disease, reflecting amyloid-β biology associated with plaque deposition. Reduced levels of Aβ42 in blood or cerebrospinal fluid are associated with increased amyloid deposition in the brain, a key step in the disease’s development. Tracking Aβ42 provides insight into amyloid pathology and is essential for understanding disease stage, progression, and response to amyloid-targeting therapies.
Elevated GFAP levels indicate astroglial activation, which often accompanies and amplifies neuroinflammatory processes in Alzheimer’s and related disorders. By measuring GFAP, researchers gain valuable information about the brain’s immune response and the extent of glial involvement in neurodegeneration.
NfL is released into the blood when neurons are damaged or undergoing degeneration. As a sensitive marker of axonal injury, increased NfL levels signal active neurodegeneration, not only in Alzheimer’s disease but also in a range of other neurodegenerative disorders. Measuring NfL allows for the assessment of ongoing neuronal damage, making it valuable for disease monitoring and evaluating therapeutic interventions.
The APOE4 genetic variant is the strongest known inherited risk factor for late-onset Alzheimer’s disease with important implications for disease trajectory and therapeutic risk, including amyloid-related imaging abnormalities (ARIA). Determining APOE4 status helps stratify risk, personalise monitoring strategies, and inform decisions about prevention and intervention.
The NULISAqpcr AD 5-plex Assay enables researchers to develop the next generation of testing:
Earlier identification of AD relevant biology
Improved biological staging across the AD continuum
Longitudinal monitoring of disease progression and therapeutic response
Enhanced screening and enrichment of clinical trial participants
Scalable deployment beyond specialized research centers
Experience NULISAqpcr AD 5-plex Assay through our Technology Access Program (TAP).
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.
